Delphinidin induces antiproliferation and apoptosis of endometrial cells by regulating cytosolic calcium levels and mitochondrial membrane potential depolarization. Issue 4 (15th October 2018)

• Record Type: Journal Article
• Authors: Park, Sunwoo; Lim, Whasun; Song, Gwonhwa
• Is Part Of: Journal of cellular biochemistry. Volume 120:Issue 4(2019)
• Page Start: 5072
• Page End: 5084
• Publication Date: 2018-10-15
• Subjects: apoptosis -- delphinidin -- End1/E6E7 -- mitochondrial dysfunction -- VK2/E6E7; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.27784
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: Endometriosis is a benign gynecological disease of women of reproductive ages, wherein endometrial cells grow ectopically, decreasing their quality of life due to chronic pelvic pain and severe dysmenorrhea. Although surgery and hormone therapies are gold standards for treating endometriosis, side effects are common and the recurrence rate is nearly 50%. Recent studies are exploring phytochemicals as pharmacological adjuvants for treating endometriosis. Delphinidin is an anthocyanin with anti‐inflammatory, antioxidative, and anticancerous properties. In this study, delphinidin showed antiproliferative and apoptotic effects on human endometrial cells. Additionally, treatment with delphinidin decreased the mitochondrial membrane potential and increased cytosolic calcium levels in VK2/E6E7 and End1/E6E7 cells. Delphinidin decreased the phosphorylation of proliferative signaling molecules, including ERK1/2, AKT, P70S6K, and S6, while increasing the phosphorylation of P38 MAPK and P90RSK. These results imply that delphinidin is a novel therapeutic agent for treating and managing endometriosis, and has fewer side effects. Abstract : Delphinidin inhibited cell proliferation and increased the population of cells in the sub G0/G1 phase in human subjects with endometriosis. It also increased the number of apoptotic cells by inducing DNA fragmentation, loss of MMP, and calcium efflux from the mitochondria to the cytosol in VK2/E6E7 and End1/E6E7 cells. Therefore, delphinidin might be a potential adjuvant for the treatment of endometriosis.